Tissue Regenix Group Dirección
Dirección controles de criterios 2/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Danny Lee
Chief Executive Officer (CEO)
US$621.0k
Compensación total
| Porcentaje del salario del CEO | 49.1% |
| Permanencia del CEO | 4yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 4yrs |
| Promedio de permanencia en la Junta Directiva | 8.3yrs |
Actualizaciones recientes de la dirección
Recent updates
Does Tissue Regenix Group (LON:TRX) Have A Healthy Balance Sheet?
Nov 02
Tissue Regenix Group plc's (LON:TRX) Share Price Is Matching Sentiment Around Its Revenues
Jun 01Tissue Regenix Group plc's (LON:TRX) Shares Bounce 25% But Its Business Still Trails The Industry
Feb 25Is Tissue Regenix Group (LON:TRX) A Risky Investment?
Jun 10Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?
Apr 02Tissue Regenix Group plc (LON:TRX): Are Analysts Optimistic?
Nov 18
Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$1m |
| Mar 31 2024 | n/a | n/a | -US$1m |
| Dec 31 2023 | US$621k | US$305k | -US$2m |
| Sep 30 2023 | n/a | n/a | -US$2m |
| Jun 30 2023 | n/a | n/a | -US$2m |
| Mar 31 2023 | n/a | n/a | -US$2m |
| Dec 31 2022 | US$581k | US$290k | -US$3m |
| Sep 30 2022 | n/a | n/a | -US$3m |
| Jun 30 2022 | n/a | n/a | -US$4m |
| Mar 31 2022 | n/a | n/a | -US$4m |
| Dec 31 2021 | US$503k | US$290k | -US$5m |
| Sep 30 2021 | n/a | n/a | -US$8m |
| Jun 30 2021 | n/a | n/a | -US$12m |
| Mar 31 2021 | n/a | n/a | -US$12m |
| Dec 31 2020 | US$306k | US$38k | -US$12m |
Compensación vs. Mercado: La compensación total de Danny($USD621.00K) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD355.82K).
Compensación vs. Ingresos: La compensación de Danny ha aumentado mientras la empresa no es rentable.
CEO
Danny Lee (63 yo)
4yrs
Permanencia
US$621,000
Compensación
Mr. Daniel Ray Lee, also known as Danny, serves as Chief Executive Officer and Director at Tissue Regenix Group plc since November 16, 2020. He was President, US Operations at Tissue Regenix Group plc sinc...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 4yrs | US$621.00k | 0.40% £ 172.3k | |
| CFO & Executive Director | 3.8yrs | US$367.00k | 0.22% £ 94.2k | |
| Technical & Operations Director - UK | no data | sin datos | sin datos | |
| Senior Vice President | no data | sin datos | sin datos | |
| EMEA Business Director & Company Secretary | 4.9yrs | sin datos | 0.16% £ 69.3k |
4.0yrs
Permanencia media
Equipo directivo experimentado: El equipo directivo de TRX se considera experimentado (4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 4yrs | US$621.00k | 0.40% £ 172.3k | |
| CFO & Executive Director | 3.8yrs | US$367.00k | 0.22% £ 94.2k | |
| Independent Non-Executive Director | 3.8yrs | US$44.00k | 0.22% £ 97.6k | |
| Member of Orthopedic Clinical Advisory Board for US | 8.3yrs | sin datos | sin datos | |
| Independent Non-Executive Director | 3.8yrs | US$44.00k | 0.085% £ 36.8k | |
| Non-Executive Chairman | 8.8yrs | US$87.00k | 0.57% £ 247.7k | |
| Independent Non-Executive Director | 8.4yrs | US$37.00k | 0.023% £ 9.9k | |
| Member of Orthopedic Clinical Advisory Board for US | 8.3yrs | sin datos | sin datos | |
| Member of Orthopedic Clinical Advisory Board for US | 8.3yrs | sin datos | sin datos | |
| Member of Orthopedic Clinical Advisory Board for US | 8.3yrs | sin datos | sin datos | |
| Member of Orthopedic Clinical Advisory Board for US | 8.3yrs | sin datos | sin datos |
8.3yrs
Permanencia media
63yo
Promedio de edad
Junta con experiencia: La junta directiva de TRX se considera experimentada (8.3 años de antigüedad promedio).